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Ultramini abstract 
The management of antiplatelet therapy resistance currently lacks clear outlines. This review 
summarizes the treatment options for patients found to have high residual platelet reactivity 
despite receiving the recommended anti-platelet agents. It also provides the cut-off points for 
platelet function tests differentiating anti-platelet therapy “responders” from “non-
responders”. 
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The role of coronary artery bypass grafting (CABG) in the management of complex coronary 
artery disease has been validated through an unparalleled level of scrutiny. Improvement in 
patient outcomes nowadays relies on continued refinements of the surgical technique and 
modulation of adjuvant pharmacotherapy. Postoperative antiplatelet therapy (APT) is 
paramount in maintaining the revascularization benefit. Individual variability to APT, 
however, results in unpredictable platelet inhibition. Currently available platelet function tests 
(PFT) dichotomize patients into “responders” and “non-responders” based upon arbitrarily 
defined cut-off points. Not surprisingly, the incidence of APT resistance across the spectrum 
of PFTs is widely discrepant, underscoring the fact that single pathway descriptors of platelet 
aggregation fail to portray the complexity of the process. Thrombosis is the principal mode of 
failure of saphenous vein grafts (SVG) in the early postoperative period
1
. Reports on the 
increased incidence of SVG failure in patients experiencing antiplatelet agent resistance 
underscore the importance of recognizing this entity and intervening in a timely fashion. This 
review summarizes the various assay-dependent definitions of APT resistance, with their 
respective rates of occurrence. The clinical impact of on-therapy high residual platelet 
reactivity (hRPR) in the cardiac surgical arena is discussed. Finally, guidelines on individual 
tailoring of antiplatelet therapy in patients found to retain high on-therapy platelet reactivity 
are suggested herein. 
 
Methods 
The PUBMED database was searched using the following subject terms: “platelet 
function testing”, “antiplatelet”, “aspirin”, “clopidogrel”, “resistance” and “cardiac surgery”. 
Reference lists of identified publications were analyzed for additional linking studies. Priority 
was given to cohort studies and reviews. 
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Definition of anti-platelet therapy resistance 
Aspirin is the most commonly used anti-platelet agent after CABG. Its use is associated with 
a 40% reduction in bypass graft occlusions
2
, with the benefit being most evident in saphenous 
vein grafts
3, 4
. The incidences of SVG graft occlusions within the first year, when the impact 
of thrombosis is greatest, range between 7.4% and 26%
5-7
. This angiographic outcome is 
accompanied by a 20%-30% reoccurrence of angina
8
 and a 5.9% need for repeat 
revascularization within the first year
9
. The current guidelines on postoperative APT 
recommend the initiation of 100-325 mg of aspirin within 6 hours of surgery
10
. In patients 
unable to take aspirin, 75 mg of clopidogrel is the suggested alternative
10
. 
The importance of prompt postoperative institution of aspirin is underscored by the fact that 
starting aspirin on the third postoperative day or later is unlikely to reflect favorably on graft 
patency
11,12
. The one-size-fits all recommendation for perioperative APT in the current 
guidelines, however, disregards the individual response variability. 
The term aspirin resistance denotes the drug’s inability to effectively suppress 
cyclooxygenase 1 (COX-1) dependent thromboxane A2 (TxA2) production. Aspirin’s failure 
to act on its pharmacological target originates from variable enteral absorption, COX-1 gene 
mutations, drug-drug interactions, patient non-compliance, accelerated post-cardiopulmonary 
bypass (CPB) platelet turnover and TxA2-independent platelet activation pathways
13, 14
. The 
prevalence of aspirin resistance varies widely in the literature, due to variable platelet agonists 
used in testing and different aspirin-related platelet function descriptors (Table 1). 
Clopidogrel is an inactive prodrug that undergoes extensive conversion into its active 
metabolite by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme
15
. It irreversibly inhibits 
the P2Y12 adenosine diphosphate (ADP) receptor, which is one of the pivotal routes of platelet 
activation. Difficulties in elucidating the true incidence of clopidogrel resistance parallel those 
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for aspirin, as it is also assay-dependent. P2Y12 receptor, ABCB1 and CYP2C19 genetic 
polymorphisms affect clopidogrel pharmacodynamics
15,16
. Strategies moving beyond 
phenotype-directed into genotype-directed tailoring of APT have become available, but 
currently lack validation in larger trials
16
. Clopidogrel’s metabolic activation is also altered by 
medications acting as substrates for CYP3A4. Significant reductions in the clopidogrel-
induced inhibition of platelet aggregation have been noted in patients using atorvastatin and 
proton pump inhibitors. Conflicting data on the clinical relevance of such interactions have 
been published17-22. Antiplatelet agent response is best perceived as a continuous variable. The 
efficacy of APT, however, may be assessed in relation to cut-off points discriminating 
between “resistance” and “response”, or by measuring the on-therapy percent platelet 
inhibition and comparing it to values obtained prior to APT. The drawback of the latter 
strategy is that it is affected by variability in baseline platelet reactivity. In contrast, strict cut-
off values are invariably arbitrarily defined, but do allow for comparing outcomes in a binary 
model. The definition of antiplatelet agent resistance remains a moving target. Lordkipanidze 
et al compared six different platelet function tests to determine the prevalence of aspirin 
resistance, and found a poor mutual correlation between individual tests
23
. A succinct 
overview of the cut-off points defining antiplatelet agent resistance using different PFTs is 
presented in Table 1. Distinguishing between cardiac surgical patients in whom APT 
resistance is permanent from those in whom it may be a temporary phenomenon may hold 
practical value. The distinction between the two can be made by comparing preoperative to 
postoperative PFT results. In patients found to have on-therapy hRPR preoperatively, the 
resistance is likely a permanent one. Conversely, adequate preoperative platelet inhibition 
followed by early postoperative hRPR may suggest that the phenomenon is transient in 
nature. Our group has shown a consistent increase in postoperative platelet reactivity 
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evaluated with aggregometry in comparison to preoperative values
24
 , which is suggestive of 
heightened platelet reactivity induced by surgery.  
 
 
Clinical impact of anti-platelet therapy resistance 
Aspirin-resistant TxA2 synthesis has been found to elevate the risk of stroke, 
myocardial infarction and cardiovascular death in patients with cardiovascular disease
25
. A 
graded increase in the aforementioned risk was observed with each increasing quartile of 
urinary 11-dehydro thromboxane B2 (UTxB2), which is a metabolic surrogate of TxA2 
activity
25
.  
Investigators in the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After 
off-pump procedures) trial noted an alarming correlation between graft occlusion and 
antiplatelet therapy resistance (RR 3.6, 95% CI 2.5 to 6.9; P <0.001)
5
. Conversely, synergistic 
aspirin- and clopidogrel-induced platelet inhibition was found to predict SVG patency (RR 
5.1, 95% CI 1.4 to 16.3; P <0.01)
5
. The link between SVG occlusion and platelet 
hyperreactivity on aspirin was reported as the secondary objective of the Reduction in Graft 
Occlusion Rates (RIGOR) study
13
. A higher incidence of early SVG occlusion was found in 
patients taking aspirin who had increased levels of UTxB2 and shear-dependent platelet 
activation
13
.  
Clopidogrel resistance has also been found to be clinically significant by several 
investigators. Adverse cardiovascular events adjudicated at 6-months were found to be more 
common in clopidogrel-resistant patients undergoing primary angioplasty for acute 
myocardial infarction
26
. High platelet reactivity to adenosine-diphosphate (ADP) on dual anti-
platelet therapy (dAPT) increased cardiovascular mortality (HR 2.55, [95% CI 1.08 to 6.07], 
P<0.034) and nonfatal myocardial infarction (HR 3.36, [95% CI 1.49 to 7.58], P<0.004) at 
 7
12-month follow-up in a similar clinical setting
27
. A more comprehensive overview of the 
clinical impact of APT resistance is provided in Table 1. Clopidogrel cessation is advocated in 
anticipation of elective cardiac surgery in order to minimize perioperative blood loss
10
. One 
must recognize that this, however, is potentially hazardous as it may induce a rebound 
prothrombotic and proinflammatory state
28
. Mahla et colleagues proved that clopidogrel can 
safely be continued up to surgery provided that residual on-therapy platelet reactivity 
evaluated by thromboelastography remained high
29
. Analogously, Di Dedda et al recently 
documented that 32% of patients scheduled for cardiac surgery retained hRPR on clopidogrel 
30
. These observations again add credence to APT monitoring, as it may directly influence the 
preoperative discontinuation of clopidogrel and possibly lead to a revision of current 
guidelines.  
 
Management options for antiplatelet agent resistance 
With the problem of antiplatelet agent resistance lacking a clear outline and definition, it is 
not surprising that guidelines for its management remain to be formed. While a large 
proportion of the evidence examining the impact of APT resistance is either observational in 
nature or comes from the non-surgical arena, there are two prospective randomized trials that 
will provide more data on the augmentation of antiplatelet therapy in drug-resistant CABG 
patients
31, 32
. The former
31
 has reached the data analysis stage, while the latter
32
 is still 
recruiting patients. Coronary bypass grafts may be especially vulnerable in the immediate 
postoperative period, and there is growing evidence that antiplatelet therapy resistance should 
not be ignored. The first step in individualized tailoring of platelet inhibition should be 
platelet function testing at approximately 7 days of APT initiation (Figure 1). Once hRPR is 
recognized, extrinsic factors such as patient non-compliance, drug interactions or suboptimal 
glucose and cholesterol regulation should be ruled out.  
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As antiplatelet drug resistance may be a temporary manifestation, one course of action is to 
re-evaluate the drug effect without changing the current platelet inhibition regime. Within 
seven days both aspirin and unbolused clopidogrel reach steady state drug levels. We, 
therefore, recommend repeating platelet function testing 7 days after any PFT result that is 
outside the desired therapeutic window. 
A significant proportion of patients recognized as clopidogrel resistant 24 hours after its 
institution were found to respond to the drug when re-evaluated at 30 days
33, 34
. Likewise, the 
proportion of CABG patients found to be aspirin resistant is inversely proportional to the time 
elapsed between its assessment and the procedure itself
35, 36
. This point again brings into focus 
the importance of isolating patients with permanent from those with transient postoperative 
APT resistance. In the event that a follow-up evaluation of platelet function shows persistence 
of low-responsiveness, different lines of management should be explored.  
An effective approach to antiplatelet therapy resistance is to increase the drug dose. In 
diabetic patients found to be hyporesponsive to 100 mg of aspirin, increasing the dose to 300 
mg led to superior platelet inhibition (Platelet Function Analyzer closure time increased from 
170±45 to 229±75 seconds, P<0.001)
37
. Increased loading and maintenance doses of 
clopidogrel have also been found to surmount the resistance to lower-dose therapy
15, 38
. 
Doubling the dose of clopidogrel in patients found to be non-responders to 75 mg, effectively 
inhibited platelets in 60% of patients
39
. Neubauer et al reduced the incidence of clopidogrel 
resistance from 23.6% to 5% by modification of the administered dose based on an 
aggregometer-guided algorithm
38
. The conversion of non-responders using this strategy, 
however, remains unpredictable, which emphasizes the need for re-evaluating the 
effectiveness of platelet inhibition after the implemented dose change
39
. The BOCLA-plan 
(Bochum Clopidogrel and Aspirin Plan) incorporating a “test and treat” strategy effectively 
eliminated aspirin resistance by dose modification and subsequent platelet function testing
40
. 
 9
Of the 19.4% patients found to be low-responsive to 100 mg of aspirin, 94.6% were converted 
to responders by increasing the dose to 300 mg
40
. The remaining 5.4% received effective 
platelet inhibition by further increasing the dose to 500 mg of aspirin
40
. It is important, 
however, to acknowledge the potential of high-dose aspirin to worsen endothelial-mediated 
arterial dilatation
41
. A similar protocol was implemented for the 30.8% of patients found to be 
resistant to 75 mg of clopidogrel. Increasing the dose to 150 mg, in line with the predefined 
BOCLA-plan, induced effective platelet inhibition in 69% of previously resistant patients
40
. 
 
Finally, an attractive solution to the problem of hRPR on one platelet inhibitor is to 
either add a different agent in order to induce an additive effect, or to substitute the original 
drug altogether. The different mechanisms of platelet inhibition targeted by aspirin and 
thienopyridines allow for cumulation of their individual anti-aggregational effects. Mannacio 
et al showed that dAPT effectively overcame single drug resistances, with a subsequent 
reduction in SVG occlusion (7.4% vs. 13.1%; P=0.04)
5
. Patients randomized to dAPT in the 
CRYSSA trial experienced similar rates of both minor (2% vs. 1.3%, P=0.5) and major 
bleeding episodes (1.3% vs. 1.3%, P=1.0) in comparison to the aspirin-monotherapy group
5
. 
The safety of dAPT was corroborated by similar chest tube outputs in both treatment arms 
(115±80 ml in the aspirin group vs. 125±70 ml in the dAPT group (P=0.2))
5
. The 
administration of clopidogrel on the background of aspirin therapy in the early postoperative 
period did not increase the rate of re-exploration or transfusion in a study by Chan et al
42
 .  
Commonly utilized protocols include starting dAPT when chest tube drainage has been ≤50 
ml for 2 hours 
5, 42
. We would recommend exercising caution in restarting clopidogrel, 
however, in patients on preoperative dAPT with documented profound ADP inhibition. Our 
group has documented that preoperative Multiplate ASPI test values <20 area under the curve 
units (AUC) and ADP test <73 AUC predicted higher postoperative chest tube output43. 
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While clopidogrel and aspirin account for the most commonly used combination of 
antiplatelet drugs, the potential advantages of novel agents may lead to a future revision of 
that paradigm. New generation P2Y12 inhibitors are less susceptible to genetic polymorphisms.  
Clopidogrel requires two CYP-mediated oxidative steps to reach its active metabolite, 
while prasugrel requires only one. It initiates faster and more potent platelet inhibition, with 
less inter-patient response variability than its predecessor
44.  The TRITON-TIMI 38 study 
(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with 
Prasugrel–Thrombolysis In Myocardial Infarction 38) demonstrated prasugrel’s superiority 
over clopidogrel in the reduction of major adverse cardiovascular events (MACE) in patients 
with acute coronary syndromes (ACS) (HR 0.81; [95% CI, 0.73 to 0.90]; P<0.001)
45
. The 
reduction in MACE was offset by an increased risk of bleeding
45
. The post hoc analysis of 
patients in the prasugrel treatment arm who underwent CABG, mirrored the general study 
population’s increased bleeding risk
46
. Overall mortality, however, was significantly lower in 
the prasugrel than the clopidogrel CABG cohort despite comparable risk profiles (adjusted 
OR: 0.26 [95% CI, 0.08 to 0.85]; P=0.025)
46
. A potential problem in interpreting these results 
is that all-cause mortality was as high as 8.67% in the clopidogrel cohort, which had a mean 
EuroSCORE of only 3.6±3.2
46
. This caveat is amplified by the fact that EuroSCORE may 
even overestimate CABG mortality
46,47
. Nevertheless, prasugrel’s highly effective platelet 
inhibition and very low incidence of non-responsiveness make it a suitable candidate for 
patients found to be resistant to prior antiplatelet therapy. In the BOCLA study, patients found 
to be clopidogrel resistant to even an augmented dosing regime, benefited from the addition of 
prasugrel in achieving the targeted antiplatelet effect
40
. 
 
Ticagrelor is absorbed as an active agent, and is therefore unaffected by the 
idiosyncrasies of intrinsic biotransformation. Its prompt and reversible P2Y12 inhibition was 
responsible for a significant reduction in adverse events in its direct comparison to clopidogrel 
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in the Study of Platelet Inhibition and Patient Outcomes (PLATO) (HR 0.84; [95% CI, 0.77 to 
0.92]; P<0.001)
48
. The ticagrelor cohort had a 22% relative reduction in mortality
48
. The 
incidence of bleeding in the CABG subgroup was not affected by ticagrelor, presumably due 
to the reversible nature of its P2Y12 inhibition
48
. It has already been shown to be useful in 
upgrading antiplatelet therapy in patients found to be clopidogrel hyporesponders
49
. In the 
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of 
Switching Therapies (RESPOND) trial it has provided more uniform and enhanced platelet 
inhibition in comparison to clopidogrel, practically eliminating on-therapy hRPR
49
.  
Prompt induction of platelet inhibition can be achieved with cangrelor. It is a direct-
acting P2Y12 inhibitor that immediately suppresses platelet aggregation
50. Its effect is quickly 
reversible upon the drug’s discontinuation
50.  Cangrelor’s intravenous mode of administration 
overcomes the variability in enteral absorption and bioavailability seen in patients with acute 
hemodynamic compromise
51
.  Additionally, its very short half-life (3 to 5 minutes) allows for 
precise bridging of anti-platelet therapy in patients scheduled for elective cardiac surgery, 
without increasing the risk of major bleeding
52
. While the pharmacokinetic properties of 
cangrelor make it unsuitable for long-term management of APT resistance, its potential 
applicability in the acute perioperative setting warrants mentioning. 
Redundancy and parallel activation pathways characterize clot formation. The role of 
thrombin in the process of thrombosis goes beyond the generation of fibrin, as it is a very 
potent platelet agonist. Its platelet activation effects are mediated by protease-activated 
receptor PAR-1
53
. Vorapaxar is a novel antiplatelet agent that inhibits platelet aggregability 
by targeting PAR-1. In the Thrombin Receptor Antagonist in Secondary Prevention of 
Atherothrombotic Ischemic Events (TRA 2P)–Thrombolysis in Myocardial Infarction (TIMI) 
50 trial, voraxapar reduced the incidence of death or adverse ischemic events over placebo on 
the background of standard therapy (HR 0.87; [95% CI, 0.80 to 0.94]; P<0.001)
53
.  It 
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increased the risk of bleeding, including intracranial hemorrhage
53
. Exploiting alternative 
routes of platelet inhibition may be reasonable in patients found to be resistant to the more 
commonly targeted platelet receptors.  
Since the activation of clopidogrel is dependent upon CYP3A4, it stands to reason that 
pharmacologic induction of this enzyme’s metabolic activity may convert clopidogrel non-
responders into responders
54
. Co-administration of rifampin and clopidogrel has been used to 
explore and prove this concept in healthy volunteers
54
. Whether this approach is of any value 
in the cardiac surgical population is as of yet unknown.  
 
Discussion 
 
Despite the absence of an all-encompassing method for defining antiplatelet response, 
there is sufficient evidence to support wider dissemination of tools designed to quantify on-
therapy platelet reactivity. Strategies utilizing platelet function tests in order to guide 
transfusion therapy, reduce bleeding and tailor antiplatelet therapy are gaining momentum in 
the modern cardiac surgical practice
55,56
. Platelet aggregability after cardiac surgery is 
inconsistent over the early postoperative period. Its unpredictable nature stems from the 
integration of several opposing influences. The effects of postoperative platelet depletion and 
iatrogenic platelet inhibition are counterbalanced by accelerated post-CPB platelet turnover. 
Longitudinal follow-up of platelet reactivity is, therefore, a useful adjunct to standard 
postoperative protocols aiming to achieve optimal patient outcomes.  
Antiplatelet therapy resistance may offset the benefits of surgical myocardial 
revascularization. Point-of-care platelet function tests provide timely information regarding 
residual platelet reactivity. Unfortunately, individual PFTs provide data that is not always 
reciprocated by other tests. This brings into focus the need for standardization and clinical 
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validation of each test. It is unlikely that different PFTs will ever provide completely 
interchangeable results because of the large variability of platelet activation pathways that are 
being tested. Recognizing the impact of APT resistance, however, should serve as an impetus 
for the definition of its management algorithms. While APT resistance after cardiac surgery 
may be a transient phenomenon, it occurs during the period when graft patency is most 
vulnerable. Dual antiplatelet therapy or incremental drug increases in conjunction with regular 
platelet function testing are useful in overcoming this problem. The contemporary expansion 
of the antiplatelet drug armamentarium will likely translate into superior outcomes in the 
clinical domain. The benefits of enhanced platelet inhibition must be balanced against an 
increased risk of bleeding, which is bound to be its unwanted, yet inevitable, corollary. 
In summary, we advocate the use of point-of-care platelet function testing, and 
tailoring of antiplatelet therapy. Prospective accumulation of data on the clinical impact of 
such strategies is sorely needed in order for them to become validated on a larger scale.  
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Table 1. Antiplatelet therapy resistance: assay-specific definitions, prevalence and clinical impact 
 
 
Study 
Patient 
population 
Aspirin resistance Clopidogrel resistance Cut-off value for APT resistance Outcome 
    Incidence 
Platelet function 
test 
POC turn-
around time 
Incidence 
Platelet function 
test 
POC turn-
around time 
Aspirin Clopidogrel   
Mannacio et 
al
5
 
OPCAB pts 
(n=300) 
32.6% (5 days 
after treatment 
inititation) 
 VerifyNow 
Aspirin 
(Accumetrics Inc, 
San Diego, CA) 
<10 min 
22%* (5 days 
after treatment 
initiation) 
 VerifyNow 
P2Y12 
<10 min 
Aspirin reaction 
units >550  
P2Y12 resistance 
units >230 and 
platelet 
inhibition >30% 
APT resistance predicted graft 
occlusion (RR 3.6, 95% CI 2.5 to 6.9; 
p<0.001). 
Sambu et al
57
 
Stent 
thrombosis 
pts (n=39) 
28% (at 
inclusion) 
Short TEG 
(Haemonetics 
Corp, 
Massachusetts, 
USA) 
15 min 
67%† (at 
inclusion) 
Short TEG 
(Haemonetics 
Corp, 
Massachusetts, 
USA) 
15 min 
<50% TEG 
percent platelet 
inhibition 
<30% TEG per 
cent platelet 
inhibition 
Inclusion criterion was stent 
thrombosis 
Gluckman et 
al
13
 
CABG pts 
(n=229) 
5% (at 3 days 
postoperatively); 
0.9% (at 6 mo 
postoperatively) 
AA induced 
platelet 
aggregometry 
(Chrono-Log, 
Havertown, PA)  
7 min 
Not reported Not reported N/A 
>1 Ohm Not reported 
No correlation between APT 
resistance and SVG patency 
16% (at 3 days 
postoperatively); 
10% (at 6 mo 
postoperatively) 
VerifyNow 
Aspirin 
(Accumetrics Inc, 
San Diego, CA) 
<10 min 
Aspirin reaction 
units ≥550  
Not reported 
No correlation between APT 
resistance and SVG patency 
64% (at 3 days 
postoperatively); 
12% (at 6 mo 
postoperatively) 
PFA-100 CEPI 5-8 min 
CEPI clotting 
time (CT) ≤193 s  
Not reported 
SVG occlusion was more prevalent in 
subjects with CADP CT≤88s (at 6 
months); no correlation with CEPI 
73% (at 3 days 
postoperatively); 
31% (at 6 mo 
postoperatively) 
UTxB2 N/A 
UTxB2 ≥400 
pg/mg creatinine 
Not reported 
ASA-insensitive TXA2 generation, 
measured by UTxB2, predicted SVG 
thrombosis  
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Petricevic et 
al
24
 
CABG pts 
(n=99) 
31.3% 
(preoperatively); 
46.5% (at 4 days 
postoperatively) 
ASPI test 
Multiplate 
(Dynabyte Gmbh 
, Munich , 
Germany) 
9 min Not reported Not reported N/A ≥30 AUC
‡
 Not reported Not reported 
Preisman et 
al
58
 
CABG pts 
(n=59) 
44% 
(preoperatively) 
TEG platelet 
mapping 
(Haemoscope 
Corporation, 
Niles, IL, USA) 
up to 1 hour 
85% 
(preoperatively) 
TEG platelet 
mapping 
(Haemoscope 
Corporation, 
Niles, IL, USA) 
up to 1 hour 
AA induced 
platelet 
activation >50%   
ADP induced 
platelet 
activation >50%   
MAadp <42.5 mm predicted 
increased postoperative bleeding 
Lordkipanidze 
et al23 
Stable 
coronary 
disease 
(n=201) 
4% LTA (AA) N/A 
Not reported Not reported N/A 
residual platelet 
aggregation 
>20%  
Not reported Not reported 
10.3-51.7%  LTA (ADP) N/A 
residual ADP-
induced platelet 
aggregation 
>70%  
18% 
Whole blood 
aggregometry 
(Chronolog) 
7 min >3 Ohms 
59,50% PFA 100 5-8 min 
Aperture closure 
time <193 sec 
6,70% 
VerifyNow 
Aspirin 
(Accumetrics Inc, 
San Diego, CA) 
<10 min 
Aspirin reaction 
units ≥550  
22,90% 
urinary 11-
dehydro-
thromboxane B2 
concentration 
(dTxB2) 
N/A 
≥67.9 ng/mmol 
of creatinine  
Kempfert et 
al
59
 
CABG/OPCAB 
pts, (n=59) 
28.8% 
(preoperatively); 
49.2% (at 5 days 
postoperatively) 
Turbidimetric 
aggregometry 
(PAP-4, Berlin, 
Germany) 
N/A Not reported Not reported N/A 
platelet 
aggregation 
>30% despite in 
vitro addition of 
25µM ASA to 
exclude non-
compliance 
Not reported 
3 deaths occured after 12 months 
follow up. All were perioperatively 
found to be aspirin resistant 
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Bednar et al
60
 
CABG/OPCAB 
pts, (n=80) 
Not reported 
PAP-4 Platelet 
Aggregation 
Profiler (BioBata 
Corp) 
N/A Not reported Not reported N/A 
Platelet 
aggregation was 
assessed as 
continuous 
variable without 
cut off for 
clopidogrel 
resistance 
Not reported 
Non significant relationship between 
platelet aggregation studies and 
chest tube discharge in 24 hours was 
noted 
Poston et al
61
 
OPCAB pts 
(n=76) 
3% 
preoperatively; 
13.2% 
postoperatively 
(at 3 days 
postoperatively) 
TEG platelet 
mapping 
(Haemoscope, 
Niles, IL) 
up to 1 hour Not reported Not reported N/A 
>1 SD above the 
normal value  
Not reported
 II
 %MAASA (TEG)  higher in pts with 
occluded grafts (55±22 vs. 22±17, 
P=0.05); WBA %Ohm 6 min-low vs. 
high dose (69±25 vs. 35±20, P=0.05) 
higher in pts with occluded grafts 
Whole blood 
aggregometry 
(Chronolog , 
Havertown, PA 
7 min Not reported Not reported N/A 
>1 SD above the 
normal value 
Not reported 
Di Dedda et 
al
30
 
Cardiac 
surgery pts 
(n=344) 
Not reported Not reported N/A 
32% 
preoperatively 
ADP test 
Multiplate 
(Dynabyte Gmbh, 
Munich , 
Germany) 
9 min Not reported 
§
> 60% of lower 
limit of normal 
range (last 
clopidogrel dose 
within 1 day); 
ADP test >32 U. 
The last ADP test result before the 
operation was significantly 
associated (p=0.002) with 
postoperative bleeding and the need 
for postoperative platelet 
concentrate transfusions; 
Thrombotic events not reported 
§
>70% of lower 
limit of  normal 
range (last 
clopidogrel dose 
2 days); ADP test  
>37 U. 
§
>80% of lower 
limit of normal 
range (last 
clopidogrel dose 
3 days prior to 
the test); ADP 
test >43 U. 
§
platelet 
aggregation 
within normal 
range (>53 U); 
last dose of 
clopidogrel >4 
days  
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Abbreviations: AA – arachidonic acid; ADP – adenosine diphosphate; CABG – coronary artery bypass grafting; CEPI – collagen/epinephrine agnosts; LTA – light 
transmittance aggregometry; OPCAB – off pump coronary artery bypass; POC – point-of-care; PFA – platelet function analyzer; TEG – thromboelastography 
*in CRYSSA 12.6% of patients were resistant to both aspirin and clopidogrel 
†In CREST 26% of patients were resistant to both aspirin and clopidogrel 
‡Multiple WBA provides 3 parameters: velocity, area under the curve (AUC) and percent platelet inhibition. AUC provides the greatest diagnostic yield
62
. Several studies 
report cutoff values delineating aspirin resistance using Multiplate
63-65
 
§ Cut-off values were adjusted for number of days following preoperative clopidogrel discontinuation and expressed as percentage of the normal range value of ADP test as 
indicated by manufacturer (53-122 U (AUC)) 
II
Gurbel et al investigated the prognostic value of thromboelastography (MAadp) in assessment of ischemic events among patients undergoing PCI. MAadp >47 mm was 
found to be the best predictor of ischemic events (receiver operating curve, AUC=0.84 [95% CI 0.78 – 0.89, p < 0.0001])
66
. 
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Figure 1. Algorithm summarizing management options for patients with documented 
antiplatelet therapy resistance.  
 
PFT, platelet function testing; IPA, inhibition of platelet aggregation; hRPR, high residual platelet reactivity; 
APA, antiplatelet agent; APT, antiplatelet therapy  
 
 

